Format

Send to

Choose Destination
Neuron. 2011 May 26;70(4):597-613. doi: 10.1016/j.neuron.2011.05.007.

Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone.

Author information

1
Department of Neurosciences and Division of Neurosurgery, City of Hope National Medical Center & Beckman Research Institute, Duarte, CA 91010, USA.

Abstract

Since their discovery twenty years ago and prospective isolation a decade later, neural stem cells (NSCs), their progenitors, and differentiated cell derivatives along with other stem-cell based strategies have advanced steadily toward clinical trials, spurred by the immense need to find reparative therapeutics for central nervous system (CNS) diseases and injury. Current phase I/II trials using stem cells in the CNS are the vanguard for the widely anticipated next generation of regenerative therapies and as such are pioneering the stem cell therapy process. While translation has typically been the purview of industry, academic researchers are increasingly driven to bring their findings toward treatments and face challenges in knowledge gap and resource access that are accentuated by the unique financial, manufacturing, scientific, and regulatory aspects of cell therapy. Solutions are envisioned that both address the significant unmet medical need and lead to increased funding for basic and translational research.

PMID:
21609819
DOI:
10.1016/j.neuron.2011.05.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center